<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01473173</url>
  </required_header>
  <id_info>
    <org_study_id>CJ_APA_101</org_study_id>
    <nct_id>NCT01473173</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, PK, PD of Escalating Single and Multiple Oral Doses of CJ-12420 in Healthy Male Subjects</brief_title>
  <official_title>A Phase I, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study, to Investigate the Safety, Tolerability, PK and PD of Escalating Single and Multiple Oral Doses of CJ-12420 in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CJ HealthCare Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CJ HealthCare Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study are:

        -  To evaluate the safety and tolerability of single and multiple oral doses of CJ-12420 in
           healthy male subjects.

        -  To evaluate the single- and multiple-dose PK of orally administered CJ-12420 in healthy
           male subjects.

        -  To evaluate the single- and multiple-dose PD of orally administered CJ-12420 in healthy
           male subjects.

        -  To compare the multiple-dose pharmacodynamics (PD) of orally administered CJ-12420 and
           esomeprazole in healthy male subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the PK, PD, safety and tolerability of escalating single and multiple oral doses of CJ-12420 in healthy male subjects</measure>
    <time_frame>Throughout the study</time_frame>
  </primary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">59</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>CJ-12420 50mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose
8 volunteers will be administered CJ-12420 50mg or placebo comparators.(CJ-12420:placebo=6:2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CJ-12420 100mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose
8 volunteers will be administered CJ-12420 100mg or placebo comparators.(CJ-12420:placebo=6:2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CJ-12420 200mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose
8 volunteers will be administered CJ-12420 200mg or placebo comparators.(CJ-12420:placebo=6:2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CJ-12420 400mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose
8 volunteers will be administered CJ-12420 400mg or placebo comparators.(CJ-12420:placebo=6:2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CJ-12420 100mg (repeated dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Repeat doses
100mg is the anticipated dose
8 volunteers will be administered CJ-12420 100mg or placebo comparator.(CJ-12420:placebo=6:2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CJ-12420 200mg (repeated dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Repeat doses
200mg is the anticipated dose
8 volunteers will be administered CJ-12420 200mg or placebo comparator.(CJ-12420:placebo=6:2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Esomeprazole 40mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>8 volunteers will be administered Esomeprazole 40mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CJ-12420</intervention_name>
    <arm_group_label>CJ-12420 50mg</arm_group_label>
    <arm_group_label>CJ-12420 100mg</arm_group_label>
    <arm_group_label>CJ-12420 200mg</arm_group_label>
    <arm_group_label>CJ-12420 400mg</arm_group_label>
    <arm_group_label>CJ-12420 100mg (repeated dose)</arm_group_label>
    <arm_group_label>CJ-12420 200mg (repeated dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esomeprazole 40mg</intervention_name>
    <arm_group_label>Esomeprazole 40mg</arm_group_label>
    <other_name>Nexium</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male volunteers in the age between 20 and 45 years old (inclusive)

          -  Body mass index (BMI) in the range of 19 to 28 kg/m2 and weighing at least 50 kg

          -  Medically healthy with no clinically significant vital signs (sitting position blood
             pressure, pulse rate) (90 mmHg ≤ systolic blood pressure ≤ 140 mmHg, 50 mmHg ≤
             diastolic blood pressure ≤ 95 mmHg, 45 beats per minute ≤ pulse rate ≤ 95 beats per
             minute)

          -  Non-smokers or non-users of nicotine-containing products for at least 3 months

        Exclusion Criteria:

          -  History of clinically significant gastrointestinal, renal, hepatic, neurologic,
             hematologic, endocrine, oncologic, pulmonary, immunologic, psychiatric,
             musculoskeletal or cardiovascular disease or any other condition, which, in the
             opinion of the Investigator, would jeopardize the safety of the subject or impact the
             validity of the study results

          -  History of allergy or sensitivity to any drug, including any prior serious adverse
             reaction to PPIs (e.g. omeprazole, rabeprazole, lansoprazole)

          -  History of symptomatic GERD, erosive esophagitis, duodenal ulcer, gastric ulcer,
             Barrett's esophagus or Zollinger-Ellison syndrome, previous positive H. pylori
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyun-Seop Bae, MD, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 14, 2011</study_first_submitted>
  <study_first_submitted_qc>November 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2011</study_first_posted>
  <last_update_submitted>April 9, 2013</last_update_submitted>
  <last_update_submitted_qc>April 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 10, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Safety</keyword>
  <keyword>Tolerability</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Pharmacodynamics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esomeprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

